NVO
Novo Nordisk
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NYSE: NVO
- PEG Ratio
Novo Nordisk currently trades with a PE to growth ratio of 0.69, based on Jul 24, 2026 data. Dividing the 11.58 PE ratio by the 16.8% earnings growth rate produces this figure. Relative to the 2.76 average from the past four quarters, the PEG ratio has dropped by 75%.
NVO PEG ratio history
Historically, Novo Nordisk has a PEG ratio averaging 3.29 across the last ten years. At 0.69, today's PEG ratio sits 79% less than its historical average. The ten years high came in the Mar 2019 quarter at 16.69, reflecting peak valuation relative to growth. The bottom was reached in the Mar 2026 quarter at 0.52, suggesting attractive value relative to growth during that period.
Novo Nordisk PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 8.25 | 14.03 | 1.7% |
| 2024 | 1.27 | 27.21 | 21.4% |
| 2023 | 0.72 | 37.4 | 52.3% |
| 2022 | 2.14 | 38.31 | 17.9% |
| 2021 | 2.28 | 35.54 | 15.6% |
| 2020 | 2.42 | 23.67 | 9.8% |
| 2019 | 9.46 | 23.65 | 2.5% |
| 2018 | 4.81 | 18.77 | 3.9% |
| 2017 | 8 | 21.61 | 2.7% |
| 2016 | 1.64 | 16.89 | 10.3% |
| 2015 | 0.74 | 26.76 | 36% |
| 2014 | 4.1 | 26.25 | 6.4% |
| 2013 | 1.04 | 21.03 | 20.2% |
| 2012 | 0.76 | 22.33 | 29.5% |
| 2011 | 0.94 | 20.42 | 21.8% |
Novo Nordisk PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.52 | 8.73 | 16.8% |
| Dec 2025 | 8.25 | 14.03 | 1.7% |
| Sep 2025 | 1.54 | 15.12 | 9.8% |
| Jun 2025 | 0.73 | 17.58 | 24% |
| Mar 2025 | 1.15 | 20.35 | 17.7% |
| Dec 2024 | 1.27 | 27.21 | 21.4% |
| Sep 2024 | 1.42 | 37.99 | 26.7% |
| Jun 2024 | 1.42 | 49.33 | 34.8% |
| Mar 2024 | 0.94 | 44.43 | 47.4% |
| Dec 2023 | 0.72 | 37.4 | 52.3% |
| Sep 2023 | 0.87 | 38.23 | 43.9% |
| Jun 2023 | 1.08 | 37.1 | 34.5% |
| Mar 2023 | 1.57 | 40.11 | 25.5% |
| Dec 2022 | 2.14 | 38.31 | 17.9% |
| Sep 2022 | 2.01 | 33.01 | 16.4% |
NVO average PEG ratio chart
When comparing to historical data, NVO's PEG ratio is lower than the 3, 5 and 10-year averages.
PEG comparison
With a PEG of 0.69, NVO stands higher than the Healthcare sector, the industry and its peers average. Looking at the Healthcare sector average of 0.53, Novo Nordisk's PEG is 30% higher.
NVO EPS growth
NVO PEG vs peers
Compared to its peers, NVO has a PEG ratio lower than stocks AZN and AMGN, while greater than LLY's and GILD's. At 0.69, Novo Nordisk's PEG ratio is higher than the peer group average of 0.55.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| GILD Gilead Sciences Inc | 0.31 | $160.55B |
| LLY ELI LILLY & Co | 0.33 | $1.13T |
| BMY Bristol Myers Squibb Co | 0.52 | $126.79B |
| NVO Novo Nordisk | 0.69 | $217.76B |
| AZN Astrazeneca plc | 0.74 | $262.18B |
| AMGN Amgen Inc | 0.84 | $202.95B |
| REGN Regeneron Pharmaceuticals Inc | 8.11 | $68.78B |
| MRK Merck & Co Inc | N/A | $323.72B |
| NVS Novartis AG | N/A | $294.63B |
Frequently asked questions
What is Novo Nordisk's PEG ratio?
According to Jul 24, 2026 figures, NVO's PEG ratio stands at 0.69.
What is the 3-year average PEG ratio for Novo Nordisk (NVO)?
Historical data over a 3-year period puts NVO's average PEG ratio at 1.71.
What is the 5-year average PEG ratio for Novo Nordisk (NVO)?
Historical data over a 5-year period puts NVO's average PEG ratio at 1.82.
What is the highest PEG ratio for NVO?
NVO's PEG ratio topped out at 16.69 during the Mar 2019 quarter - the highest in ten years.
How does the current PEG ratio for NVO compare to its historical average?
Compared to the 10-year average, NVO's PEG ratio stands 79% lower.
How is NVO's PEG ratio calculated (Novo Nordisk PEG ratio formula)?
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jul 24, 2026, Novo Nordisk has a PE ratio of 11.58. Earnings grew at 16.8% over the TTM period ending Mar 2026. Applying the formula, this gives a PEG ratio of 0.69. PEG RATIO(0.69) = PE RATIO(11.58) / EPS GROWTH(16.8%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.